We have been conducting clinical trials involving recombinant human bone morphogenetic protein 2 (rhBMP-2) in the maxillary floor for the past 15 years. Trials have been completed to assess the dosing, safety, and efficacy of the material, and rhBMP-2 and autogenous grafts have been compared for their ability to support dental implants. We now have long-term studies demonstrating that rhBMP-2 induces bone functions exactly like an autograft and eliminates the need for a host donor site. The results have been predictable, and evidence has demonstrated the utility of this material in place of an autograft. Studies are underway to examine the expanded use of rhBMP-2 materials at other sites in the maxillofacial region. This presentation will provide evidence-based data to support the use of rhBMP-2 as a bone graft substitute.
R. Gilbert Triplett, DDS, PhD, is Regents Professor and chairman of the Department of Oral and Maxillofacial Surgery/Pharmacology at Baylor College of Dentistry, Texas A&M University System Health Science Center in Dallas. Dr Triplett has maintained a long-term interest in reconstruction of edentulism, implant dentistry, and bone regeneration.
Approximate Running Time: 60 minutes